Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The prediction for Incyte Corp. disappointed with a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Incyte Corp. | 0.787% | 0.787% | -5.307% | -10.252% |
iShares Core DAX® | 3.054% | -1.396% | 15.789% | 12.675% |
iShares Nasdaq 100 | 4.389% | -5.391% | 29.906% | 39.325% |
iShares Nikkei 225® | 5.386% | -3.105% | 16.065% | 8.150% |
iShares S&P 500 | 2.955% | -3.011% | 25.903% | 37.650% |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten